Genzyme Announces Sublicense Agreement with DxS

Pursues Global Expansion of Lung Cancer Testing Portfolio

New Year accolade for DxS

DxS one of the northwest’s internationally-recognised biotechnology firms has a lot to celebrate in 2008. Based at the University of Manchester Incubator Company facilities DxS has not only grown its staff by 28% inside a year and expanded its laboratory facilities, the company received a prestigious award at the recent BioNow 2007 awards evening.

DxS and Epigenomics AG enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions® Technology in DNA Methylation based Testing

The K-RAS Mutation Test Kit has now been CE-Marked and will be available for professional diagnostic use from 1st January 2008.

DxS K-RAS Mutation Detection Kit Used To Assess Tumour Mutation Status Prior to Treatment with Amgen’s Vectibix™

DxS expand their portfolio of cancer mutation products, with the launch of a B-RAF Mutation Detection Kit

DxS signs a license with Canadian company for its class leading Scorpions® technology

EGFR detection in lung cancer study confirms superior performance of DXS EGFR Kit

Tokyo Cancer Institute Hospital lung cancer study data is published in Chest

Significant step towards the delivery of diagnostics for cancer drug response

UC Davis Cancer Center presents enhanced EGFR detection data from plasma, through collaboration with DxS

K-RAS Mutation Detection Kit Launched by DxS – the industry leaders in tumour mutation analysis

DxS launch TheraScreen™ – The first CE marked diagnostic for EGFR detection